论文部分内容阅读
为了了解增殖细胞核抗原(PCNA)与前列腺癌的病理分级、临床分期及预后的关系,我们采用免疫组织化学S-P法对43例前列腺癌组织中PCNA进行检测,并与临床随访结果进行对比。结果显示:前列腺癌PCNA表达与分级、分期及预后均呈正相关(P<0.05),随肿瘤分级增高,PCNA表达呈明显上升趋势;肿瘤高分期组(Ⅲ、Ⅳ)的PCNA表达明显高于低分期组(Ⅰ、Ⅱ);PCNA高表达组(Ⅲ、Ⅳ级)术后生存率明显低于低表达组(Ⅰ、Ⅱ级)。结果表明:PCNA是判断细胞增殖程度的重要指标,对肿瘤演变、术后随访及治疗有一定的指导意义,对估计前列腺癌的恶性程度及推测预后具有重要参考价值。
To understand the relationship between proliferating cell nuclear antigen (PCNA) and the pathological grade, clinical stage and prognosis of prostate cancer, we used immunohistochemical S-P method to detect PCNA in 43 cases of prostate cancer, and compared with clinical follow-up results. The results showed that the expression of PCNA in prostate cancer was positively correlated with grade, staging and prognosis (P<0.05). With the increase of tumor grade, the expression of PCNA showed a significant upward trend; the expression of PCNA in tumor high-grade group (III, IV) was significantly higher than In the staging group (I, II), the postoperative survival rate of the PCNA high expression group (grades III and IV) was significantly lower than that of the low expression group (grades I and II). The results showed that: PCNA is an important indicator to judge the degree of cell proliferation. It has certain guiding significance for tumor evolution, postoperative follow-up and treatment, and has important reference value for estimating the degree of malignancy and predicting prognosis of prostate cancer.